ODOleg Dukhno

Oleg Dukhno

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oleg Dukhno has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of quality of life, weight loss, and evolution of comorbidities at 5 years after ring-augmented one-anastomosis gastric bypass compared with one-anastomosis gastric bypass and sleeve gastrectomy in patients with extreme obesity

    by Nur Alkrinawi, Sofyan Abu Freih, Yuval Arnon, Abu-Swis Shadi, Alex Vakhrushev, Elchanan Quint, Guy Barsky, Chaled Alnakib, Ivan Kukeev, Anton Osyntsov, et al.

    Background: The prevalence of patients with extreme obesity [body mass index (BMI) ≥ 50] has significantly increased over the past three decades, surpassing the rise in the prevalence of overweight individuals in the general population. Ring-augmented one-anastomosis gastric bypass (RA-OAGB) is a modification of standard one-anastomosis gastric bypass (OAGB) designed to enhance the durability of long-term weight-loss and potentially reduce pouch dilation, particularly in patients with extreme obesity. While short-term outcomes appear comparable to other procedures, long-term comparative data remain limited. Methods: In this retrospective single-center study, we compared patients who underwent RA-OAGB with those who underwent OAGB or sleeve gastrectomy (SG) procedures, all with a minimum follow-up of ≥5 years. Data collected included demographics, comorbidities, perioperative outcomes, long-term complications, and patient-reported quality of life. Results: A total of 111 patients were included in our study during the study period – 24 underwent RA-OAGB, 44 OAGB, and 43 SG. Loss to direct follow-up at 5 years was 15% (94/111 patients had direct follow-up), although clinical data were available for all patients through medical records. The RA-OAGB group had a higher baseline BMI than the OAGB and SG groups (55.4 vs. 51.2 and 51.3 kg/m 2 ; P = 0.006). In the unadjusted analysis, median percentage of excess weight loss (%EWL) was 74%, 63%, and 52%, respectively ( P = 0.027), while median percentage of total weight loss (%TWL) was 42.4%, 37.5%, and 28.9%, respectively ( P = 0.017). After adjustment for baseline BMI and follow-up duration, BMI was significantly lower after RA-OAGB compared with SG ( P = 0.025); RA-OAGB remained associated with greater %EWL ( P = 0.001) and %TWL ( P = 0.002) compared with SG. Adjusted associations with symptomatic gastroesophageal reflux disease (GERD) were not statistically significant. Iron-deficiency anemia was more frequent after bypass procedures than after SG. Quality of life and patient satisfaction were high across all groups, with no significant differences in Bariatric Analysis and Reporting Outcome System (BAROS) scores. Conclusion: In this retrospective single-center study, RA-OAGB was associated with greater long-term weight loss than OAGB and SG. However, given the observational design, baseline differences between groups, and limited sample size, these findings should be considered hypothesis-generating and require confirmation in larger prospective multicenter studies.

  • Open Access

    Early 60-Day Morbidity after Sleeve Gastrectomy Versus One-Anastomosis Gastric Bypass: A Propensity-Matched Single-Center Cohort of 2,382 Patients

    by Ohad Guetta, Illia Vasyliev, Anton Osyntsov, Alex Vakhrushev, Sharon Daniel, Yuval Arnon, Oleg Dukhno

    Background: Comparative data on early complications after sleeve gastrectomy (SG) versus one-anastomosis gastric bypass (OAGB) remain limited. Objective: To compare 60-day postoperative morbidity between SG and OAGB while accounting for confounding. Setting: Soroka University Medical Center, Israel. Methods: This is a retrospective cohort study assessing 60-day morbidity in patients undergoing SG and OAGB between 2009 and 2024. Propensity scores (sex, height, BMI, number of previous bariatric surgeries, smoking status, diabetes mellitus, fatty liver, hiatal hernia, cholecystectomy during index surgery, and band removal during index surgery) were used for 1:1 nearest-neighbor matching without replacement. Any potential postoperative events were flagged by utilization triggers (length of stay > 7 days, ICU admission, blood transfusion, CT or upper endoscopy within 60 days) and verified by chart review. The primary outcome of this study was any complication occurring ≤ 60 days from the operation; secondary outcomes included complication types and severity by Clavien-Dindo classification. Results: Of 3,317 patients (SG n = 1,816; OAGB n = 1,501), 1,191 matched pairs were analyzed. Overall, 60-day complications were higher after SG than OAGB (15.4% vs. 11.8%, p = 0.012). SG patients exhibited more Clavien–Dindo grade II (5.1% vs. 2.4%, p > 0.001), IIIa events (1.3% vs. 0.3%, p = 0.003) and IVb events (0.7% vs. 0.1%, p = 0.039). SG patients experienced higher rates of leak (1.8% vs. 0.8%, p = 0.019), abscess (1.2% vs. 0%, p < 0.001), pleural and abdominal fluid collection (1.2% vs. 0.3%, p = 0.007), bleeding (1.6% vs. 0.7%, p = 0.033) and dysphagia/vomiting (3.2% vs. 1.3%, p = 0.001) compared with OAGB patients. OAGB patients presented with more endoscopically diagnosed ulcers (0.7% vs. 0%, p = 0.008) and respiratory complaints (2.2% vs. 0.6%, p < 0.001) compared to SG patients. Among complicated patients, upper endoscopy within 60 days was more frequent after SG (29.3% vs. 17.3%, p = 0.005); ICU length of stay was not different between the groups (0.8 ± 5.4 days in OAGB vs. 1.2 ± 9.1 days in SG, p = 0.5). Conclusions: In a large propensity-matched single-center cohort study, SG showed higher 60-day morbidity than OAGB, primarily of intermediate severity. Limitations include retrospective design, temporal bias, trigger-based ascertainment, and lack of capture of care delivered at external hospitals.

  • Open Access

    Physiologically Based Pharmacokinetic Modeling for Predicting Drug Levels After Bariatric Surgery: Vardenafil Exposure Before vs. After Gastric Sleeve/Bypass

    by Daniel Porat, Oleg Dukhno, Sandra Cvijić, Arik Dahan

    Bariatric surgery involves major changes in the anatomy and physiology of the gastrointestinal tract, which may alter oral drug bioavailability and efficacy. Phosphodiesterase-5 inhibitor (PDE5i) drugs are the first-line treatment of erectile dysfunction, a condition associated with a higher BMI. In this paper, we examine the PDE5i vardenafil for possible post-bariatric changes in solubility/dissolution and absorption. Vardenafil solubility was determined in vitro, as well as ex vivo using aspirated gastric contents from patients prior to vs. following bariatric procedures. Dissolution was tested in vitro under unoperated stomach vs. post-gastric sleeve/bypass conditions. Lastly, the gathered solubility/dissolution data were used to produce an in silico physiologically based pharmacokinetic (PBPK) model (GastroPlus®), where gastric volume, pH, and transit time, as well as proximal GI bypass (when relevant) were all adjusted for, evaluating vardenafil dissolution, gastrointestinal compartmental absorption, and pharmacokinetics before vs. after different bariatric procedures. pH-dependent solubility was demonstrated for vardenafil with low (pH 7) vs. high solubility (pH 1–5), which was confirmed ex vivo. The impaired dissolution of all vardenafil doses under post-gastric bypass conditions was demonstrated, contrary to complete (100%) dissolution under pre-surgery and post-sleeve gastrectomy conditions. Compared to unoperated individuals, PBPK simulations revealed altered pharmacokinetics post-gastric bypass (but not after sleeve gastrectomy), with 30% lower peak plasma concentration (Cmax) and 40% longer time to Cmax (Tmax). Complete absorption after gastric bypass is predicted for vardenafil, which is attributable to significant absorption from the large intestine. The biopharmaceutics and PBPK analysis indicate that vardenafil may be similarly effective after sleeve gastrectomy as before the procedure. However, results after gastric bypass question the effectiveness of this PDE5i. Specifically, vardenafil’s onset of action might be delayed and unpredictable, negatively affecting the practicality of the intended use.


  • Open Access

    Left gastric artery embolization for recurrent massive intraluminal postoperative bleeding after revisional laparoscopic one anastomosis gastric bypass surgery

    by Ivan Kukeev, Elchanan Quint, Gilbert Sebbag, Oleg Dukhno

    Laparoscopic one-anastomosis gastric bypass (LOAGB) has gained popularity as safe weight-reduction procedure. Bleeding is the common postoperative complication. We present a successful treatment of recurrent bleeding after LOAGB by embolization of the left gastric artery (LGA) and later development of necrotizing pancreatitis. A 41-year-old patient with previous bariatric surgeries undergone LOAGB surgery with development of massive intraluminal bleeding in the postoperative period. Attempts of unsuccessful endoscopic treatment were done and the bleeding was stopped by LGA embolization. In the post-embolization period, the patients developed necrotizing pancreatitis. Postoperative bleeding is the serious complications of the bariatric LOAGB procedure. Transcatheter Arterial Embolization (TAE) is the possible treatments after unsuccessful endoscopic attempts to stop the bleeding. The technical and clinical success rates of TAE in post-gastrectomy bleeding are 100 and 79%, respectively. TAE can be successfully used to stop obstinate recurrent postoperative bleeding after a LOAGB procedure.


  • Open Access

    The Complexity of Bariatric Patient’s Pharmacotherapy: Sildenafil Biopharmaceutics and Pharmacokinetics before vs. after Gastric Sleeve/Bypass

    by Daniel Porat, Oleg Dukhno, Sandra Cvijić, Arik Dahan

    Postbariatric altered gastrointestinal (GI) anatomy/physiology may significantly harm oral drug absorption and overall bioavailability. In this work, sildenafil, the first phosphodiesterase-5 (PDE5) inhibitor, was investigated for impaired postbariatric solubility/dissolution and absorption; this research question is of particular relevance since erectile dysfunction (ED) is associated with higher body mass index (BMI). Sildenafil solubility was determined both in vitro and ex vivo, using pre- vs. postsurgery gastric contents aspirated from patients. Dissolution tests were done in conditions mimicking the stomach before surgery, after sleeve gastrectomy (post-SG, pH 5), and after one anastomosis gastric bypass (post-OAGB, pH 7). Finally, these data were included in physiologically based pharmacokinetic (PBPK) modelling (GastroPlus®) to simulate sildenafil PK before vs. after surgery. pH-dependent solubility was demonstrated with low solubility (0.3 mg/mL) at pH 7 vs. high solubility at pH 1–5, which was also confirmed ex vivo with much lower solubility values in postbariatric gastric samples. Hampered dissolution of all sildenafil doses was obtained under post-OAGB conditions compared with complete (100%) dissolution under both presurgery and post-SG conditions. PBPK simulations revealed delayed sildenafil absorption in postbariatric patients (increased tmax) and reduced Cmax, especially in post-OAGB patients, relative to a presurgery state. Hence, the effect of bariatric surgery on sildenafil PK is unpredictable and may depend on the specific bariatric procedure. This mechanistically based analysis suggests a potentially undesirable delayed onset of action of sildenafil following gastric bypass surgery.


  • Open Access

    Visceral Adipose Tissue E2F1-miRNA206/210 Pathway Associates with Type 2 Diabetes in Humans with Extreme Obesity

    by Nitzan Maixner, Yulia Haim, Matthias Blüher, Vered Chalifa-Caspi, Isana Veksler-Lublinsky, Nataly Makarenkov, Uri Yoel, Nava Bashan, Idit F. Liberty, Ivan Kukeev, et al.

    Objective: Up-regulated expression of transcription-factor E2F1 in human visceral adipose tissue (VAT) characterizes a dysmetabolic obesity sub-phenotype. An E2F1-miRNA network has been described in multiple cancers. Here we investigated whether elevated VAT-E2F1 in obesity is associated with VAT-miRNA alterations similar to, or distinct from, those described in cancer. Furthermore, we assessed if E2F1-associated miRNA changes may contribute to the link between high- VAT-E2F1 and a dysmetabolic obesity phenotype. Methods: We assembled a cohort of patients with obesity and high-VAT-E2F1, matched by age, sex, ±BMI to patients with low-VAT-E2F1, with and without obesity (8 patients/groupX3 groups). We performed Nanostring©-based miRNA profiling of VAT samples from all 24 patients. Candidate E2F1-related miRNAs were validated by qPCR in an independent cohort of patients with extreme obesity, with or without type-2-diabetes (T2DM) (n = 20). Bioinformatic tools and manipulation of E2F1 expression in cells were used to establish the plausibility of the functional VAT-E2F1-miRNA network in obesity. Results: Among n = 798 identified miRNAs, 17 were differentially expressed in relation to E2F1 and not to obesity itself. No evidence for the cancer-related E2F1-miRNA network was identified in human VAT in obesity. In HEK293-cells, overexpression/downregulation of E2F1 correspondingly altered the expression of miRNA-206 and miRNA-210-5p, two miRNAs with reported metabolic functions consistent with those of E2F1. In VAT from both cohorts, the expression of both miRNA-206 and 210-5p intercorrelated, and correlated with the expression of E2F1. In cohort 1 we did not detect significant associations with biochemical parameters. In cohort 2 of patients with extreme obesity, all those with high VAT-E2F1 showed a diabetes-complicated obesity phenotype and higher expression of miRNA-206 and miRNA-210-5p, which also correlated with fasting glucose levels (both miRNAs) and fasting insulin (miRNA-210-5p). Conclusions: Whilst the previously described cancer-related E2F1-miRNA network does not appear to operate in VAT in obesity, miRNAs-206 and 210-5p may link high-E2F1 expression in VAT with diabetes-complicated extreme obesity phenotype.


  • Human adipose tissue is a putative direct target of daytime orexin with favorable metabolic effects: A cross‐sectional study

    by Nir Goldstein, Hiroshi Tsuneki, Nikhil Bhandarkar, Eleonora Aimaretti, Yulia Haim, Kanta Kon, Kiyofumi Sato, Tsutomu Wada, Idit F. Liberty, Boris Kirshtein, et al.

    Objective: Orexin/hypocretin (Ox) and its receptors (OxR), a neuroendocrine system centrally regulating sleep/wakefulness, were implicated in the regulation of peripheral metabolism. It was hypothesized that human adipose tissue constitutes a direct target of the OxA/OxR system that associates with distinct metabolic profile(s).Methods: Serum Ox levels and abdominal subcutaneous and visceral adipose tissue expression of Ox/HCRT, OxR1/HCRTR1, and OxR2/HCRTR2 were measured in n = 81 patients.Results: Higher morning circulating Ox levels were associated with improved lipid profile and insulin sensitivity, independently of BMI (β = −0.363, p = 0.018 for BMI‐adjusted homeostatic model of insulin resistance). Adipose HCRT mRNA was detectable in HCRT expressers were mostly (80%) males and, compared with nonexpressers, had lower total and LDL cholesterol. HCRTR1 was readily detectable, and HCRTR2 was undetectable. HCRTR1 mRNA and OxR1 protein expression were higher in subcutaneous than visceral adipose tissue, and among nonobese patients, patients with obesity, and patients with obesity and T2DM were 3.4 (1.0), 0.7 (0.1), 0.6 (0.1) (AU) (p < 0.001) and 1.0 (0.2), 0.5 (0.1), 0.4 (0.1) (AU) (p = NS), respectively. Higher visceral HCRTR1 expression was associated with lower fasting insulin and homeostatic model of insulin resistance, also after adjusting for BMI. In human adipocytes, HCRTR1 expression did not exhibit significant oscillation.Conclusions: Human adipose tissue is a putative direct target of the OxA‐OxR1 system, with higher morning input being associated with improved metabolic profile.